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BACKGROUND: Non-epithelial ovarian cancers are divided into sex cord-stromal tumours (SCSTs) and germ cell tumours (GCTs).
Whereas parity and other pregnancy-related factors are protective for epithelial ovarian cancer, their associations with SCSTs and
GCTs remains unclear.
METHODS: Using data from the medical birth registries from Denmark, Finland, Norway and Sweden, we compared all parous
women with a diagnosis of SCSTs (n= 420) or GCTs (n= 345) 1970–2013 with up to 10 parous controls (SCSTs n= 4041; GCTs n=
2942) matched on the cases’ birth year and country. We used conditional logistic regression to estimate odds ratios (ORs) with 95%
confidence intervals (CIs) of associations between pregnancy-related factors and SCSTs and GCTs.
RESULTS: The risk of SCSTs, but not GCTs, decreased with higher age at last birth [≥40 versus <25 years: OR 0.48 (95% CI
0.23–0.98)]. The risk of SCSTs (but not GCTs) also decreased with shorter time since last birth. Number of births, preterm birth,
preeclampsia, and offspring size were not associated with risk of SCSTs or GCTs.
CONCLUSIONS: We found a decreased risk of SCSTs with higher age at last birth and shorter time since last birth. The risk of SCSTs
(but not GCTs) may be influenced by the woman’s reproductive history.
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BACKGROUND
Non-epithelial ovarian cancers are rare tumours that are classified
as either sex cord-stromal tumours (SCSTs) or germ cell tumours
(GCTs), each with several subtypes. The biology and tumour
development are poorly understood and rarely studied in SCSTs
and GCTs. Both are located in the interior of the ovaries, and many
of the subtypes produce hormones. SCSTs develop in women of
all ages, with a peak incidence between 50 and 55 years.1,2
Although exceptionally rare, GCTs account for the majority of the
ovarian malignancies among women <30 years and unlike SCSTs,
incidence declines with age.3
Whereas increasing number of births and higher age at birth are
protective for epithelial ovarian cancer,4,5 prior studies evaluating
SCSTs or GCTs have been largely inconsistent with respect to the
role of number of births and age at births on risk. These
inconsistencies could be due to the small number of cases studied
(typically less than 80).6–9 In the largest study published to date,
including 330 SCSTs and 149 GCTs, Adami et al. reported an
association between increasing number of births and decreased
risk of SCSTs and a borderline association with decreased risk of
GCTs.10 Intrauterine factors have been suggested to have an
impact on risk of both SCSTs and GCTs in the mother8,11 as well as
in the offspring.12,13 Hence, there is reason to further investigate
the influence of other pregnancy-related factors that might reflect
hormonal exposure during pregnancy and a women’s life, such as
pregnancy length, age at births and offspring size.
We have performed a population-based case-control study with
pooled data from four Nordic countries to allow an investigation
of a large number of non-epithelial ovarian cancer cases. Our aim
was to evaluate the risk of SCSTs and GCTs (in the mothers) in
relation to pregnancy and birth characteristics. To have a
homogenous study group with data on the factors of interest
for this study, only parous women were included. By analysing the
patterns of possible associations, we hope to increase our insight
in the development of these rare tumours.
METHODS
Outcomes and definition of cases/controls
This case-control study was based on linked data from the
nationwide and population-based medical birth registries (MBRs)
and cancer registries in a Nordic collaboration, and the methods
used have been described recently.5 The MBRs contain informa-
tion from antenatal, obstetric, and neonatal medical records and
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are based on mandatory reporting of all births since 1973
(Denmark), 1987 (Finland), 1967 (Norway), and 1973 (Sweden).14–18
The cancer registries are based on compulsory reporting of all
incident tumours and cover the entire population since 1943
(Denmark), 1953 (Finland and Norway), and 1958 (Sweden). Case
reporting is essentially complete and data validity high.19–22 The
unique identifier assigned to each citizen in the Nordic countries
at birth or upon immigration made accurate record linkages
across the registries possible.
We included women recorded with a pregnancy lasting longer
than 22 weeks in the MBRs who later developed malignant SCSTs
and GCTs and were registered in a cancer registry between 1973
and 2011 in Denmark, 1987 and 2012 in Finland, 1967 and 2013 in
Norway and 1973 and 2013 in Sweden (Table 1). Cases were free
of other cancers at time of ovarian cancer diagnosis Ovarian
cancer was defined by ICD-10/ICD-O-3 code C56.9, and by ICD-7
code 175.0 in Sweden before 1993, and ICD-O/2/ICD-O/3 codes
and WHO/HS/CAN/C24.1 codes, as defined by the International
Agency for Research on Cancer,23 were used to identify SCSTs and
GCTs (supplementary Table 1). Up to ten controls per case were
sampled among women in the MBRs with a prior pregnancy
lasting longer than 22 weeks and who were alive and cancer-free
at the time of the cases’ diagnosis. Controls were matched on
country and the birth year of the case. Data on all the women’s
pregnancies were included in the linkage to the MBRs. However,
many of the women’s first pregnancies occurred before the start
of the MBRs, so information was most complete for the most
recent pregnancy before the case’s diagnosis/matching.
Exposures
We examined the following exposures: age at first and last birth;
time since first and last birth; number of births at the time of
matching; preeclampsia and twin/triplet pregnancy (in any
pregnancy). Information on pregnancy length (in completed
weeks) and offspring’s birth length and weight were recorded
based on the most recent pregnancy before the case’s diagnosis
to evaluate the most complete data.
Statistical analyses
We estimated odds ratios (ORs) with 95% confidence intervals (CIs)
for the association between number of births and risks of
subsequent SCSTs and GCTs using conditional logistic regression
models (conditioned on birth year of the case and country).
Analyses of other pregnancy and neonatal characteristics were
analysed in models conditioned on matching factors and
additionally adjusted for number of births. Birth length/weight,
adjusted for pregnancy length (as a continuous variable), were
assessed as a measure of foetal growth. All factors were examined
as categorical variables, and as ordinal variables to test for trend
(for offspring weight, trend was tested per 500 g). In analyses of
pregnancy length, and birth length/weight of offspring, women
who were diagnosed with non-epithelial ovarian cancer within six
months after giving birth were excluded (SCSTs: six cases, GCTs: 32
cases), to minimise the possibility that associations were
influenced by preterm delivery due to cancer. We performed a
sensitivity analysis in which we excluded women who had only
given birth once, since their age at first and last birth is the same.
We also evaluated continuous time since last birth in categories of
age at last birth to better clarify the relationship between these
factors. All results were tested for heterogeneity (p-het) of
associations between countries in stratified analyses, using a
likelihood ratio test. R version 3.3.2 was used for all analyses.24
RESULTS
We identified 420 cases of SCSTs in parous women, with a median
age of 47 years (range 21–71) at diagnosis and 345 cases of GCTs
in parous women, with a median age of 37 years (range 18–79).
Maternal characteristics and data on the offspring from the most
recent pregnancy, stratified by case/control status, are presented
in Table 1.
Risk factors for sex cord-stromal tumours
Higher age at last birth was associated with decreased risk of
SCSTs [i.e. last birth at age ≥40, versus before 25 years: OR 0.48
(95% CI 0.23–0.98); per year increasing age: OR 0.97 (95% CI
0.94–0.99)]. A similar trend was seen with higher age at first birth
[first birth at age ≥30, versus before 25 years: OR 0.70 (95% CI
0.47–1.05); per year increasing age: OR 0.97 (95% CI 0.94–1.00)].
SCST risk decreased gradually with higher age at first or last birth
(Table 2). A recent childbirth (shorter time since first and last birth)
was associated with decreased risk (Table 2). Increasing number of
births was not associated with risk of SCSTs, nor were any of the
other investigated factors. All results are presented adjusted for
number of births, but unadjusted results were very similar
(supplementary Table 2).
Risk factors for germ cell tumours
Age at birth was not associated with GCTs [i.e. last birth at age
30–39 versus before 25 years: OR 1.01 (95% CI 0.68–1.49)], nor
were time since birth, number of births [per birth: OR 0.99 (95% CI
0.90–1.10)], or any of the other investigated factors.
Sensitivity analyses
We performed a sensitivity analysis for SCSTs in which we
excluded women who had only given birth once, but the results
were not altered [i.e. last birth at age 30–39, versus before 25
years: OR 0.61 (95% CI 0.41–0.90)]. The proportion SCSTs and GCTs
differed between the Nordic countries, with a higher percentage
of SCSTs in Norway and Sweden and a higher percentage of GCTs
in Denmark and Finland (Table 1). However, when we stratified
our analyses and tested for heterogeneity of associations among
countries, the ORs between the pregnancy-related factors and
SCSTs and GCTs did not differ (supplementary Table 3), suggesting
there were no major differences in coding between the countries.
We evaluated time since last birth in categories of age at last
birth and vice versa (supplementary Table 4). The pattern was
consistent across both, with reductions in risk for the recent births
(whether categorised by ≥40 age at last birth, or by <10 years
since last birth).
DISCUSSION
In this large study of non-epithelial ovarian cancer, we found that
both higher age at last birth and shorter time since last birth were
associated with decreased risk of SCSTs, but not with risk of GCTs.
There was no association between number of births or any of the
other investigated maternal or offspring factors and risk of SCSTs
or GCTs.
Sex cord-stromal tumours
The evidence of a relation between age at birth and risk of SCSTs
have so far been limited by few, and often small studies
(summarised in supplementary Table 5). In the largest study to
date, our findings of associations between higher age at last birth
and shorter time since last birth and subsequent decreased risk of
SCSTs, are, however, consistent with two smaller studies. A small
Mexican case-control study,7 (based on three cases that were over
28 years of age at their last birth), and a study of Swedish women
born 1925–1960 who were diagnosed with ovarian cancer during
1958–1984 (hence partly overlapping with this study), showed
higher age at first birth tended to be associated with a decreased
risk of SCSTs.10 In contrast, an older American study6 published in
1992 with 45 SCSTs found an increased risk with higher age at first
birth and SCSTs. In this study, nulliparous women were included,
and the results were based on only seven SCST cases that were
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over 29 years of age at their first birth, and the effect of age at last
birth was not evaluated, restricting the generalisability of the
findings.
Our finding with a lack of association between number of births
and SCSTs is consistent with three previous studies,6,8,9 although
one of them found an association between nulliparity and SCSTs,9
which we did not analyse. In addition, two other studies7,10 found
an association between increasing number of births and decreased
risk of SCSTs: The study, by Adami et al.,10 was comprised of data
from an earlier calendar period when diagnostic criteria might not
have been as well defined as today resulting in misclassified
epithelial ovarian cancer cases. The second study, by Sanches-
Zomorano et al.,7 was based on only 10 cases. All studies except
Adami et al. included nulliparous women in their analyses. In light
of our findings, and review of other studies, the impact of number
of births on risk of SCSTs seems limited.
To our knowledge, prior investigations on preeclampsia, multi-
ple birth and pregnancy length, and birth characteristics (offspring
length and weight) on risk of non-epithelial ovarian cancer have
not been performed. Our study does not, however, support
associations between these characteristics and subsequent risk of
SCSTs in the mother.
In summary, data from our large study suggest that older age at
last birth, and shorter time since last birth affect risk of SCSTs.
Results from previous studies are somewhat conflicting (sum-
marised in supplementary Table 5). A hormonal influence in this
subgroup is suggested by data from a 2011 Finnish study showing
a positive association between higher levels of testosterone,
androstenedione and 17-OH-progesterone concentrations during
Table 1. Maternal and offspring characteristics of non-epithelial
ovarian cancer patients and matched controls, Nordic countries,
1970–2013a.
Variable Sex cord-stromal
tumours
Controls Germ cell
tumours
Controls
n % n % n % n %
Total 420 100 4041 100 345 100 2942 100
Maternal
Year of birth n % n % n % n %
1925–1939 34 8.1 334 8.3 16 4.6 159 5.4
1940–1949 140 33.3 1384 34.2 46 13.3 421 14.3
1950–1959 146 34.8 1405 34.8 113 32.8 1001 34.0
1960–1969 75 17.9 702 17.4 91 26.4 752 25.6
1970–1992 25 6.0 216 5.3 79 22.9 609 20.7
Country
Denmark 51 12.1 502 12.4 96 27.8 779 26.5
Finland 13 3.1 113 2.8 34 9.9 270 9.2
Norway 96 22.9 975 24.1 83 24.1 808 27.5
Sweden 260 61.9 2451 60.7 132 38.3 1085 36.9
Age at diagnosis/matching (years)
<40 110 26.2 958 23.7 233 67.5 1817 61.8
40–49 143 34.0 1418 35.1 65 18.8 653 22.2
50–59 117 27.9 1169 28.9 32 9.3 330 11.2
≥60 50 11.9 496 15.2 15 4.3 142 4.8
Age at first birth (years)
<25 131 46.3 1173 43.6 148 54.2 1123 49.5
25–29 98 34.6 907 33.7 91 33.3 780 34.4
≥30 54 19.1 613 22.8 34 12.5 366 16.1
Missing 137 – 1348 – 72 – 673 –
Age at last birth (years)
<25 70 16.7 484 12.0 86 24.9 583 19.8
25–29 137 32.6 1235 30.6 126 36.5 1072 36.4
30–39 198 47.1 2127 52.6 123 35.7 1176 40.0
≥40 15 3.6 195 4.8 10 2.9 111 3.8
Time since first birth (years)
<10 66 23.3 567 21.1 155 56.8 1103 48.6
10–19 84 29.7 790 29.3 74 27.1 728 32.1
20–29 89 31.4 914 33.9 32 11.7 325 14.3
≥30 44 15.5 422 15.7 12 4.4 113 5.0
Missing 137 – 1348 – 72 – 673 –
Time since last birth (years)
<10 136 32.4 1187 29.4 234 67.8 1824 62.0
10–19 114 27.1 1269 31.4 72 20.9 705 24.0
20–29 127 30.2 1170 29.0 28 8.1 319 10.8
≥30 43 10.2 415 10.3 11 3.2 94 3.2
Number of births
1 80 19.0 690 17.1 92 26.7 744 25.3
2 186 44.3 1781 44.1 148 42.9 1217 41.4
3 96 22.9 1007 24.9 71 20.6 607 20.6
≥4 58 13.8 563 13.9 34 9.9 374 12.7
Preeclampsia in any pregnancy
No 386 91.9 3735 92.4 326 94.5 2778 94.4
Yes 34 8.1 306 7.6 19 5.5 164 5.6
Multiple birth in any pregnancyb
No 410 97.6 3978 98.4 337 97.7 2877 97.8
Table 1 continued
Variable Sex cord-stromal
tumours
Controls Germ cell
tumours
Controls
n % n % n % n %
Total 420 100 4041 100 345 100 2942 100
Yes 10 2.4 63 1.6 8 2.3 65 2.2
Pregnancy length (weeks)c,d
≤36 19 4.6 195 4.9 12 3.9 158 5.7
37–41 347 84.4 3381 85.7 268 86.2 2389 85.9
≥42 45 10.9 371 9.4 31 10.0 233 8.4
Missing 3 – 35 – 2 – 30 –
Offspring
Offspring length (cm)c,d
<48 31 7.6 351 8.9 17 5.5 253 9.2
48–54 357 87.7 3426 86.7 272 88.0 2361 85.4
>54 19 4.7 176 4.5 20 6.5 151 5.5
Missing 7 – 29 – 4 – 45 –
Offspring weight (g)c,d
<2500 14 3.4 160 4.0 10 3.2 125 4.5
2500–4500 384 3.2 3694 92.9 293 93.9 2575 91.9
>4500 14 3.4 124 3.1 9 2.9 102 3.6
Missing 2 – 4 – 1 – 8 –
aPercentages are presented without including missing cases.
bSex cord-stromal tumours: twin births: 10 cases/62 controls (2.4%/1.5%);
triplets or greater: 0 cases/1 control (0%/0.02%). Germ cell tumours: twin
births: 8 cases/63 controls (2.3%/2.1%); triplets or greater: 0 cases/2
controls (0%/0.07%).
cData from last pregnancy.
dExcludes cases diagnosed with ovarian cancer within six months after
giving birth (sex cord-stromal tumours: six cases, germ cell tumours: 32
cases).
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pregnancy and risk of SCSTs.11 However; effects of 17-OH-
progesterone might differ from those of progesterone, and timing
of hormonal exposure in pregnancy may be important. Another
Finnish study25 measured hormone levels during the first
trimester in women with singleton pregnancies, and found that
maternal age was associated with sex steroids concentrations,
with higher progesterone concentrations and lower androgen and
oestradiol in women >30 years of age. An American study from
2008,26 found similar results with a positive association between
higher maternal age and levels of progesterone, and inverse
associations with androgen and oestrogen. This could be a
possible explanation for the decrease in risk of SCSTs with higher
age at last birth, with progesterone levels associated with a
decrease in risk and androgens with an increase in risk. A risk
decrease with increasing progesterone levels has been raised as a
potential protective factor for epithelial ovarian cancer through
cell clearance of pre-malignant cells (reviewed in ref. 27) and
indicates similar mechanisms for SCSTs and epithelial ovarian
cancer. The increased risk with increasing androgen and oestradiol
concentrations is generally consistent with SCSTs being rare
before puberty, when hormone levels are low. These hormones
are likely needed for tumour development or progression.
Germ cell tumours
Our finding of a lack of association between age at birth and GCTs
is consistent with two previous studies.7,10 A Norwegian cohort
study, including 71 cases of GCTs diagnosed 1960–1991 (hence
partly overlapping with our study),8 found an increased risk of
GCTs with high-aged childbirths. This result was, however, based
on only 40 parous women. As in previous studies,6–8,10 we saw no
association between number of births and GCTs. Neither did we
see any associations between the analysed pregnancy and birth
characteristics and subsequent risk of GCTs in the mother.
To summarise, a woman’s reproductive history does not seem
to influence her risk of GCTs. Gonadal dysgenesis is associated
with risk of GCTs,28,29 but not SCSTs. This suggests that
development of GCTs is more genetically controlled, given that
gonadal dysgenesis is secondary to chromosomal anomalies or
mutations in genes related to the urogenital ridge or sex
differentiation.28 This genetic component may also explain why
there are no specific reproductive risk factors for GCTs, as opposed
Table 2. Risk of non-epithelial ovarian cancer by subtype for
pregnancy, perinatal and birth characteristicsa.
Sex cord-stromal
tumours
Germ cell
tumours
Cases/controls 420/4041 (54.9%) 345/2942
(45.1%)
Mean/median age at diagnosis
(range)
48/47 (21–71) 39/37 (18–79)
OR 95% CI OR 95% CI
Age at first birth (years)
<25 1.00 Ref 1.00 Ref
25–29 0.91 0.67–1.24 0.98 0.71–1.34
≥30 0.70 0.47–1.05 0.93 0.59–1.47
Per year age 0.97 0.94–1.00 1.01 0.98–1.05
Age at last birth (years)
<25 1.00 Ref 1.00 Ref
25–29 0.77 0.55–1.08 1.03 0.72–1.46
30–39 0.64 0.45–0.90 1.01 0.68–1.49
≥40 0.48 0.23–0.98 0.82 0.31–2.16
Per year age 0.97 0.94–0.99 1.01 0.98–1.04
Time since first birth (years)
<10 0.53 0.23–1.19 1.20 0.36–3.96
10–19 0.69 0.35–1.35 1.03 0.34–3.15
20–29 0.80 0.47–1.38 0.96 0.37–2.53
≥30 1.00 Ref 1.00 Ref
Per year 1.03 1.00–1.07 0.99 0.95–1.02
Time since last birth (years)
<10 0.78 0.40–1.53 0.81 0.23–2.78
10–19 0.70 0.39–1.25 0.76 0.24–2.48
20–29 0.97 0.60–1.56 0.61 0.21–1.81
≥30 1.00 Ref 1.00 Ref
Per year 1.04 1.01–1.06 0.99 0.96–1.02
Number of births
1 1.00 Ref 1.00 Ref
2 0.97 0.72–1.29 1.19 0.88–1.60
3 0.89 0.64–1.24 1.19 0.83–1.70
≥4 0.96 0.65–1.41 0.95 0.60–1.50
Per birth 0.96 0.87–1.05 0.99 0.90–1.10
Preeclampsia in any pregnancy
No 1.00 Ref 1.00 Ref
Yes 1.09 0.75–1.58 1.08 0.65–1.78
Multiple birth in any pregnancy
No 1.00 Ref 1.00 Ref
Yes 1.49 0.75–2.98 1.16 0.55–2.47
Pregnancy length (weeks)b,c
≤36 0.91 0.55–1.49 0.72 0.39–1.33
37–41 1.00 Ref 1.00 Ref
≥42 1.18 0.84–1.64 1.23 0.82–1.85
Per week 1.03 0.97–1.09 1.07 1.00–1.14
Offspring length (cm)b,c,d
<48 0.90 0.59–1.37 0.64 0.37–1.13
48–54 1.00 Ref 1.00 Ref
>54 1.02 0.62–1.68 1.11 0.67–1.83
Per cm 1.04 0.99–1.09 1.02 0.96–1.07
Table 2 continued
Sex cord-stromal
tumours
Germ cell
tumours
Cases/controls 420/4041 (54.9%) 345/2942
(45.1%)
Mean/median age at diagnosis
(range)
48/47 (21–71) 39/37 (18–79)
OR 95% CI OR 95% CI
Offspring weight (g)b,c,d
<2500 0.79 0.41–1.50 88 0.98 0.46–2.07
2500–4500 1.00 Ref 1.00 Ref
>4500 1.13 0.64–1.98 0.78 0.38–1.58
Per 500 g 1.05 0.94–1.15 1.06 0.93–1.18
aOdds ratio (OR) and 95% confidence intervals (CIs) from conditional
logistic regression models, conditioned on birth year (of the case) and
country, adjusted for number of births.
bData from last pregnancy.
cExcludes cases diagnosed with ovarian cancer within six months after
giving birth (sex cord-stromal tumours: six cases, germ cell tumours: 32
cases).
dAdjusted for pregnancy length (last pregnancy) as a continuous variable.
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to SCSTs. Changes in hormone levels during puberty might play a
role, while the greater alterations during pregnancy have a more
limited ability to affect risk because affected individuals would
need to be very young at childbirth.
Strength and limitations
This population-based study is based on the largest number of
SCSTs and GCTs reported to date. Despite the comparably larger
sample size, statistical power was still limited, and confidence
intervals were often wide suggesting that even larger studies
are needed to reach firmer conclusions about associations that are
likely modest. The cases numbers also limited our ability to
separate the effect of the correlated factors of higher age at last
birth and shorter time since last birth.
Among the strengths of this study is the almost complete
information on the studied perinatal factors, based on mandatory
reporting to birth registries which avoids recall bias. The nation-
wide cancer registries in the four Nordic countries22 enabled
identification of cancer cases in a similar and standardised
manner. However, the proportions SCSTs and GCTs differed
between the Nordic countries, which could imply differences in
coding, genetics, or other risk factors, although there was no
evidence of heterogeneity in the ORs by country.
While there are few, if any, established risk factors for non-
epithelial ovarian cancer, it is unclear if the current study was missing
information on important confounding factors, such as obesity,
breast-feeding and oral contraceptive use. Oral contraceptives are
associated with decreased risk of epithelial, and possible non-
epithelial, ovarian cancer,6,30,31 but since data are scarce, their impact
on SCSTs and GCTs remains uncertain. We also lacked information
on oophorectomy/salpingectomy or hysterectomy, and thus could
not exclude controls that had undergone gynaecological surgery.
However, since the prevalence of women having gone through a
oophorectomy/hysterectomy in the Nordic countries is low (200 per
100,000 women), and probably even lower in this young cohort, it is
unlikely to have had a major effect on our risk estimates.32 Because
our aim was to study the impact of pregnancy-related factors on risk
of SCSTs and GCTs, we only included parous women in our study
and results are thus generalisable to parous women only. This
resulted in a higher mean age of GCT cases than in the general
population and our inability to investigate the influence of early
pregnancy loss (prior to week 22).
CONCLUSIONS
In this population-based case-control study, including 420 cases of
SCSTs and 345 cases of GCTs among parous women, higher age at
last birth, and shorter time since last birth, were both associated
with a decreased risk of SCSTs, similar to results for epithelial
ovarian cancer. Thus, it is possible that hormonal mechanisms or
other mechanisms related to this aspect of reproductive history
influence the development of both SCSTs (but not GCTs) and
epithelial ovarian cancer. Number of births was not associated
with the risk of SCSTs or GCTs. We found no associations with any
of the investigated pregnancy-related factors and GCTs, suggest-
ing that reproductive factors may have limited impact on risk of
these uncommon tumours.
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